New documents have investigators questioning inconsistencies and omissions in data reporting in the PLATO trial, building on ...
An investigation published in The BMJ raises new concerns over the landmark clinical trial (PLATO) that was used to gain ...
An investigation published by The BMJ today raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the ...
A top selling antiplatelet drug has never quite shaken off doubts about its advantage over cheaper rivals. With generic versions of ticagrelor about to launch, Peter Doshi takes a fresh look at the ...
Germany: A recent cohort study published in JAMA Network Open has shed light on the comparative outcomes of ticagrelor and ...
A new study supports previous data demonstrating the superiority of prasugrel over ticagrelor in reducing the composite ...
Ticagrelor has saved the lives of thousands of heart attack patients around the world. Its journey from discovery over twenty years ago to world-wide treatment was the product of one of the largest ...
The goal of DrugSorb-ATR, an investigational medical device, is to reduce the severity of perioperative bleeding in patients on ticagrelor (Brilinta ®, AstraZeneca) undergoing coronary artery ...
The results of PLATO (A Study of Platelet Inhibition and Patient Outcomes) 1 provide a major advance in our understanding of ADP receptor inhibition with the novel agent ticagrelor. When compared ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback